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Tables 
Table 1. Particle size distribution, surface charge and entrapment efficiencies for liposome 
preparations  
Abbreviations: nm, nanometers; mV, millivolts; Lipo, liposome; OPC, octyl-palmitoyl 
chitosan, Fe, iron  
 
 
 
Formulation Mean particle size Zeta potential Entrapment efficiency
(nm) * (mV) * (%) *
Lipo-blank 253 ± 17 -28.6 ±8.77
Lipo-Fe 204 ± 22 -9.82 ± 4.33
OPC-Lipo 304 ± 15 33.1 ± 6.39 72.8 ± 1.93
OPC-Lipo-Fe 209 ± 12  27.8 ± 8.67 82.7 ± 2.7
* Values are means ± standard deviation, n = 3
Figure Legends 
 
Figure 1 FT-IR spectra of chitosan 5k (red) and o-palmitoyl chitosan (black). 
 
Figure 2 H-NMR spectra of a) chitosan 5k (panel a) and b) o-palmitoyl chitosan. 
 
Figure 3 DSC thermogram of a) chitosan (50 °C/min) and b) o-palmitoyl chitosan (20 °C/min). 
 
Figure 4 X-ray powder diffractograms of a) chitosan and b) o-palmitoyl chitosan. 
 
Figure 5  Caco-2 cell viability assessed by MTT assay following a) 48 h and b) 72 h 
incubation with liposome formulations containing increasing drug concentrations (mean ± 
S.D., n = 6). 
 
Figure 6 Iron absorption by Caco-2 cells incubated with liposome formulations: Intracellular 
ferritin was measured as a marker of iron absorption by ELISA following 22 h incubation after 
iron uptake experiments. Results are shown as mean ± S.D. (n = 6), * and † indicates 
significant difference (P < 0.05). 
 
Figure 7 Confocal microscopy images of Caco-2 cells following incubation with coumarin-6 
loaded (a-c) conventional (Lipo-Cou) liposomes and (d-f) OPC liposomes (OPC-Lipo-Cou). 
Images (a) & (d) demonstrate cell nuclei stained with TO-PRO-3 (blue), images (b) & (d) 
show cell cytoplasm with accumulated liposomal coumarin-6, and images (c) & (f) show 
merged images. Scale shown is 50 μM. 
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Abstract 
A novel chitosan derivative, O-palmitoyl chitosan (OPC) was synthesized from chitosan and palmitoyl 
chloride using methane-sulfonic acid as a solvent. The success of synthesis was confirmed by Fourier 
transform infra-red (FT-IR) spectroscopy and proton NMR spectroscopy (H-NMR). Liposomes 
encapsulating ferrous sulphate as a model hydrophilic drug for intestinal delivery were prepared with 
or without OPC inclusion (Lipo-Fe and OPC-Lipo-Fe). Entrapment of iron was significantly higher in 
OPC containing liposomes compared to controls. Quantitative iron absorption from the OPC 
liposomes was significantly higher (1.5-fold P< 0.05) than free ferrous sulphate controls. Qualitative 
uptake analysis by confocal imaging using coumarin-6 dye loaded liposomes also indicated higher 
cellular uptake and internalization of the OPC-containing liposomes. These findings suggest that 
addition of OPC during liposome preparation creates robust vesicles that have improved 
mucoadhesive and absorption enhancing properties. The chitosan derivative OPC therefore provides 
a novel alternative for formulation of delivery vehicles targeting intestinal absorption. 
 
Keywords: Liposomes, Caco-2, Ferrous sulphate 
 
Introduction 
Liposomes are formed from the spontaneous reordering and organization of phospholipid molecules 
in an aqueous medium that results in the formation of vesicles comprising one or more lipidic bilayers 
and an aqueous core.1 Bioactive molecules can either be encapsulated within the core, or 
incorporated within the phospholipid bilayer/bilayer interphase. Since they are composed of 
biologically-similar lipids, liposomes are non-toxic, biocompatible and biodegradable as a carrier 
system.2 Liposomes thus represent an attractive delivery system for pharmaceutical applications 
where they can be utilized for targeted and controlled drug delivery, and in the cosmetic and food 
industry where the focus is on protection of the active ingredient and enhanced permeability and 
absorption.3,4 The lipid composition of liposomes can also affect the level of incorporation of 
drug/substances perhaps by affecting the packaging of vesicular bilayers. 5 
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Although liposomes are capable of incorporating both hydrophilic and hydrophobic drugs, 
encapsulation of hydrophilic molecules is most challenging, partly due to loss of drug in the external 
aqueous phase during liposome formulation.6 This issue is further exacerbated in the case of ferrous 
iron whereby the metal iron-lipid interaction is known to have a detrimental effect on the integrity of 
the lipid bilayer.7 Ferrous sulphate is a hydrophilic drug that is commonly used for iron 
supplementation therapy, most often via oral delivery. Its utility is severely limited by its ability to 
cause adverse gastrointestinal events.8,9 Others have also reported low iron absorption from lipid 
based iron delivery products when used as oral iron supplements.10  
The polycationic biopolymer chitosan has been explored and employed in a number of liposome 
systems to improve their physiochemical stability and cellular uptake characteristics.11-15 Chitosan is a 
natural polysaccharide obtained by alkaline deacetylation of chitin, the major component of 
crustacean shells.16 It has an excellent biocompatibility profile due to its biodegradable nature; within 
the body it is metabolised by a number of enzymes (e.g. lysozyme, di-N-acetylchitobiase, N-acetyl-
beta-d-glucosaminidase and chitiotriosidase).17,18 In addition, chitosan has strong mucoadhesive 
properties due to the presence of amine groups in its structure which lead to electrostatic interactions 
with the negatively-charged cell surfaces, with resultant bioadherence.19,20 Chitosan coating onto the 
surface of micro or nanoparticles is therefore frequently used as a strategy to facilitate increased 
gastrointestinal uptake.21,22 Surface coating of liposomes with chitosan has also been shown to 
improve vesicle stability. Chitosan adsorbs strongly on the vesicle surface due to interplay between its 
amine groups and the negatively charged phospholipid polar heads.23 Unmodified chitosan however 
is limited in that the surface coating it forms on the liposomes is prone to rapid degradation in the 
gastric environment, thus affecting vesicle integrity and impairing the utility of these carriers for oral 
delivery applications.7  
Chitosan is only soluble in dilute acids, which limits formulation approaches and hence its 
applications.11 Several studies have sought to improve the physical and chemical characteristics of 
chitosan by conjugating hydrophobic or hydrophilic moieties to its structure, such as alkyl groups, poly 
(ε-caprolactone), and poly (ethylene glycol) (PEG).24,25 Acylation of chitosan can be carried out at the 
amino (NH2) group, the hydroxy (OH) group or at both (N, O acyl chitosan) to obtain hydrophobic 
derivatives that are soluble in organic solvents such as chloroform, acetone, and dichloromethane. 
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These chemical modifications have led to the development of novel chitosan derivatives that have 
further widened its drug delivery applications.  
In this study we synthesized and characterized a novel hydrophobic chitosan derivative, O-palmitoyl 
chitosan (OPC), and used this to formulate liposomes loaded with ferrous sulphate as a model 
hydrophilic drug. Cytotoxicity as well as qualitative and quantitative drug uptake from the liposomes 
was evaluated in vitro using the human intestinal cell line Caco-2. 
 
Materials and methods 
Materials 
Chitosan (chitosan oligosaccharide, Mol. Wt: Above 5k by viscosity method) was obtained from Kitto 
Life Co., Korea and egg phosphatidylcholine (egg PC) was obtained from Lipoid (Ludwigschafen, 
Germany). Palmitoyl chloride, ferrous sulphate, coumarin-6, cholesterol and all other chemicals, 
reagents and solvents were of analytical or cell culture grade, and purchased from Sigma-Aldrich 
(UK). Caco-2 cells were purchased from European Collection of Cell Cultures (Catalogue no. 
09042001, ECACC, UK). Ferritin ELISA kit (Product code S-22) was from Ramco (ATI Atlas, UK) and 
BCA protein assay kit (Product no. 23225) was from Pierce (Thermo Fisher Scientific, UK). Cell 
culture media, foetal calf serum (FCS) and reagents were from Invitrogen (UK). Cell culture plastic 
ware was purchased from Nunc (Denmark) or Corning (Netherlands). All reagents used were 
prepared using ultrapure water (resistivity of 18.2 MΩ cm). Prior to use, all glassware and utensils 
were soaked in 10% HCL and rinsed with ultrapure water to remove any potential traces of residual 
minerals. 
 
Methods 
Synthesis of O-palmitoyl chitosan (OPC) 
OPC was synthesized from chitosan and palmitoyl chloride using methane-sulfonic acid as a solvent 
in order to protect the amino groups of chitosan. Chitosan was dissolved in methane sulfonic acid at 
room temperature for 1 h and palmitoyl chloride was added dropwise with continuous stirring. The 
molar ratio of the repeating unit of chitosan to palmitoyl chloride was 1:2. The reaction mixture was 
kept under stirring conditions for 5 h, before terminating the reaction by adding crushed ice. The 
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resultant mixture contained OPC along with residual products such as unreacted chitosan, unreacted 
palmitoyl chloride; chitosan reacted with methane sulfonic acid, etc. Methane sulfonic acid was 
removed using sodium bicarbonate while the other impurities were removed using dichloromethane 
and chloroform to extract OPC from the mixture. Organic solvents were then evaporated using a 
rotary evaporator (Hei-VAP Advantage Rotary Evaporator, Schwabach, Germany) and the product 
dialyzed against distilled water for 2-3 days using dialysis tubing of molecular weight cut off 7000 Da 
(membrane size 7000/3, diameter 28 mm, Medicell International, UK). The dialyzed product was then 
lyophilized for 24 h (−40 ºC) using a VirTis AdVantage 2.0 bench top freeze dryer (SP Industries, UK) 
to obtain pure OPC. 
 
Polymer characterization 
H-NMR spectroscopy  
Proton NMR spectroscopy was performed on OPC using a Bruker 400 Ultra Shield spectrometer 
(Bruker UK, UK). For measurements, chitosan was dissolved in deuterium oxide (D2O) and OPC was 
dissolved in deuterated chloroform (CDCl3) and spectra were obtained at room temperature. 
 
Fourier-transform infra-red (FT-IR) spectroscopy 
FT-IR spectra were collected at room temperature using a Perkin Elmer Spectrum 100 spectrometer 
(Perkin Elmer, UK). Data were analyzed using the Perkin Elmer Spectrum Express software (Perkin 
Elmer, UK). 
 
Differential scanning calorimetry (DSC) 
In order to determine the thermal properties of the reactant, chitosan and the product, OPC, DSC 
experiments were performed using a DSC Q2000 module (TA Instruments, USA). Samples of 
approximately 5 mg (accurately weighed) were loaded onto aluminium hermetic pans. The thermal 
properties of chitosan were studied at a scan rate of 50 ºC /min and O-palmitoyl chitosan was studied 
at 10 ºC/min. Both the materials were heated from -20 ºC to 200-300 ºC under a nitrogen atmosphere. 
 
X-Ray powder diffraction  
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The solid state properties of chitosan and OPC were measured by powder X-ray diffraction studies 
using an Oxford Diffraction Xcalibur novaT X-ray diffractometer (Agilent Technologies, UK) which 
were processed using CrysalisPro software (Oxford Diffraction, Oxford, UK) and scanned at a step 
size of 10°2-theta. 
 
Preparation of iron-loaded liposomes 
Blank and iron-loaded liposomes were prepared by the thin-film hydration method, with some 
modifications.26 Egg PC (200 mg) and cholesterol (20 mg) were dissolved in a round bottomed flask 
containing 5 mL chloroform. OPC (20 mg) was simultaneously dissolved in the chloroform for 
preparation of OPC liposomes. Organic solvent was removed using a rotary evaporator (Hei-VAP 
Advantage Rotary Evaporator, Schwabach, Germany) under reduced pressure (10 min, 60 °C) 
yielding a lipid film on the walls of the flask. The lipid film was hydrated by adding a pre-warmed 
aqueous ferrous sulphate solution dropwise and shaking the flask vigorously while maintaining at 60 
°C. The lipid suspension was then transferred into a glass vial and agitated gently in an ultrasonic 
bath for 3 min after which size reduction was performed using a probe sonicator (80% sonication 
power, 20 s on and off intervals). The samples were allowed to stand for 1 h, followed by 
centrifugation to remove the unentrapped drug. The 4 liposome formulations prepared: blank 
liposome (Lipo-blank), iron-containing liposomes (Lipo-Fe), liposomes incorporating OPC (OPC-Lipo) 
and iron-containing OPC-liposomes (OPC-Lipo-Fe) were stored in nitrogen purged glass vials at 4 °C. 
For uptake visualization studies coumarin-6 loaded liposomes (Lipo-Cou and OPC-Lipo-Cou) were 
prepared using similar methodology. 
 
Determination of entrapment efficiency 
Iron entrapment efficiency (EE) was determined as described previously.27,28 Briefly, liposome 
preparations were centrifuged (13,000 rpm, 30 min, 4 °C) and aliquots of the supernatant collected to 
quantify unassociated drug. Ferrous iron levels in the solution were measured spectrophotometrically 
at 572 nm using the ferrozine method.29 Coumarin-6 concentration was determined using a microplate 
fluorimeter (Fluostar Optima, BMG Labtech, Germany) at 450 nm/505 nm (excitation/emission). The 
means of three independent readings were recorded and results expressed as mean ± standard 
deviation (SD). 
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Entrapment efficiency (EE) was calculated using Eq. (1): 
 
EE (%) =    Unbound drug in supernatant                                               Eq. (1) 
                        Total drug added  
 
Liposome physicochemical characterization  
Size analysis 
Size distribution determination of the liposomes by dynamic light scattering (DLS) was carried out 
using the Zetasizer Nano ZS (Malvern Instruments, UK). Prior to measurements the liposome 
dispersion was diluted using MQ H2O. All measurements were performed at 25°C, and three readings 
were taken for each sample to calculate mean particle size and standard deviations (SD). 
 
Zeta potential  
Zeta potential of the liposome dispersions was determined by measuring their electrophoretic 
mobilities using the Zetasizer Nano ZS (Malvern Instruments, UK). Measurements were carried out in 
triplicate at 25°C. All samples were diluted in water (1:10) before measuring the zeta potential. 
 
Cytotoxicity assay 
The potential toxic effects of liposome formulations on Caco-2 cells were assessed by carrying out the 
colorimetric 4,5-dimthylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assay, incubating Caco-2 
cell monolayers with liposome formulations diluted to final iron concentrations of 20, 50 and 100 µM 
(and equivalent volumes of corresponding blank liposomes) in phenol red free media for 48 and 72 
h.28,30 Following incubation, 20 µL MTT (5 mg/mL) was added to each well and the plates incubated 
for a further 4 h. Media was then carefully aspirated and cell monolayers solubilized with DMSO (100 
µL/well). The purple formazan product formed was quantified by measuring the absorbance 
spectrophotometrically at 550 nm to give an estimate of cell viability. 
 
Caco-2 cell iron absorption/Quantitative cellular uptake 
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Caco-2 cells were obtained at passage 20 and used experimentally between passages 35 to 55. 
Stock cultures were maintained in 75 cm2 tissue culture flasks in complete medium (Dulbecco’s 
modified Eagle’s medium (DMEM) - Glutamax®, pH 7.4 supplemented with 10% FCS, 1% 
antibiotic/antimycotic solution and 25 mM HEPES) in an incubator at 37 °C in an atmosphere of 95% 
air and 5% CO2 at constant humidity. Caco-2 cell uptake experiments were carried out as described 
previously and lysed samples were stored for analysis.28,30 Total ferritin concentration of cell lysates 
was determined using a RAMCO ferritin ELISA kit following the manufacturer’s protocol with 
modifications.28 The protein content of Caco-2 cells was determined using the Pierce BCA kit 
following the manufacturer’s protocol. Ferritin concentration was standardized against total protein 
concentration and ng ferritin/mg protein was considered an index of liposomal iron uptake and 
absorption by Caco-2 cells. 
 
Cellular uptake visualization/Qualitative cellular uptake 
Qualitative cellular uptake visualization studies were carried out as described previously with 
modifications.31 The Caco-2 cell uptake experiment was carried out as described in the previous 
section, replacing Fe-loaded liposomes with coumarin-6 liposomes (Lipo-Cou). Briefly, Caco-2 cell 
monolayers were washed twice with sterile Dulbecco’s phosphate buffered saline (DPBS), fixed with 
3% paraformaldehyde solution and washed again twice with DPBS before cell permeabiliisation 
solution (0.5 % Triton X-100 in DPBS) was added for 5 mins. Cells were then washed again with 
DPBS before being incubated with a 5% BSA block solution containing RNAse A (final concentration 
10μl/mL). Cells were then incubated with Lipo-Cou and OPC-Lipo-Cou formulations diluted in DPBS 
at a concentration of 1 µg/mL for 2 h at 37 °C. Cell nuclei were stained with TO-PRO-3 (1 μM; Life 
Technologies, UK) for 1 h at room temperature. Caco-2 cells were then examined under a confocal 
microscope (Leica TCS SP2, Leica Microsystems, UK). The coumarin 6 and TO-PRO-3 were 
investigated at 488/520 nm and 642/661nm wavelength (excitation/emission), respectively. 
Images were analyzed using the Leica LCS Lite software suite (Leica Microsystems, UK). 
 
Statistical analysis 
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Data are presented as mean ± SD, and differences between samples was analyzed by one-way 
ANOVA followed by Tukey’s post hoc test using the PRISM software package (Version 6, Graphpad 
Software Inc., San Diego, USA). Results were considered significantly different if P ≤ 0.05. 
 
Results  
The FT-IR spectra of chitosan and OPC are shown in Figure 1. The important peaks for chitosan are: 
the broad peak from 3200-3500 cm-1, signifying the free hydroxyl and amine groups of chitosan. The 
small peak at 2871 cm-1 signifies the acyl groups, while the peak at 1649 cm-1 signifies carbonyl 
stretching of an amide bond, suggesting acyl substitution at the amino group of chitosan. The low 
intensity of the peak suggests that the degree of acetylation of chitosan is low.32 The FT-IR spectrum 
of OPC differs from that of chitosan. The broad peak at 3200-3500 cm-1 is much reduced in OPC 
signifying substitution of the hydroxyl and amino groups of chitosan. There are two sharp peaks at 
2919 cm-1 and at 2851 cm-1, which signify the palmitoyl (acyl) groups, indicating acylation of chitosan. 
The sharp peak at 1740 cm-1 signifies ester bond formation, which suggests that the substitution of 
the palmitoyl groups has occurred at the hydroxy groups of chitosan.33 The peak at 1657 cm-1 
signifies amide bond formation is low in intensity, suggesting that the degree of N-acylation of 
chitosan is low.32 These FTIR results confirm the successful synthesis of OPC. 
The H-NMR spectrum of chitosan 5k (Figure 2a) shows the characteristic peaks for chitosan which 
occur between 1.8 - 5.2 ppm.33 The peak at 1.97 was assigned to the N-acetyl proton of N-acetyl 
glucosamine while the peak at 2.63 was assigned to a proton of N-acetyl glucosamine or glucosamine 
residues. The peaks from 3.3 – 4.0 ppm were assigned to the ring protons and the peaks at 4.38 and 
4.40 ppm were assigned to protons of glucosamine and N-acetyl glucosamine respectively.32 The 
peak at 4.60 ppm is the D2O solvent peak. The H-NMR spectrum of OPC (Figure 2b) differs from that 
of chitosan. The peaks at 0.86, 1.24 and 1.59 ppm were assigned to characteristic alkyl protons of the 
palmitoyl residue.33 The peak at 0.86 ppm was assigned to the protons of the terminal carbon of the 
alkyl chain i.e. [CH3- R] of the palmitoyl residue, while the peak at 1.24 ppm was assigned to the 
protons of the middle carbon i.e. [ –CH2-] of the alkyl chain of the palmitoyl residue. The peak at 1.59 
ppm was assigned to the protons of the carbon attached to the carbonyl carbon i.e. [-(CO)-CH2-] of 
the palmitoyl residue.32 The peak at 7.24 ppm was the solvent peak for CDCl3. The H-NMR data thus 
confirm the formation of OPC. 
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The DSC thermogram of chitosan (Figure 3a) showed a small endothermic peak at 70.6 °C and a 
broad endothermic peak at 100-150 °C which indicates loss of unbound and bound water.34 There 
was also a sharp endothermic peak at 243.5 °C which indicates thermal degradation of the sample.35 
The DSC thermogram of OPC (Figure 3b) did not show any thermal transitions from 0-160 °C. The 
thermogram showed a sharp endothermic peak at 182 °C, indicating polymer decomposition.36 
The X-ray diffractogram of chitosan (Figure 4a) showed peaks at 2Θ=9, at 2Θ=20 and at 2Θ=23 
which were characteristic for chitosan.32,35 The diffractogram suggested that chitosan was crystalline. 
The X-ray diffractogram of OPC (Figure 4b) showed a broad peak at 2Θ=21. The peaks at 2Θ=9 and 
2Θ=23 which were seen in chitosan have disappeared. The diffractogram suggested that OPC was 
crystalline and that o-acylation had slightly altered the chitosan structure.35 
Both iron-containing liposome formulations demonstrated high iron entrapment efficiency (EE). The 
EE of Lipo-Fe was 72.8 ± 1.93 %, which was increased and in case of OPC-Lipo-Fe at 82.7 ± 2.70 % 
(P<0.05; Table 1). Mean hydrodynamic diameters of all liposomes were in the range 204-304 nm 
following sonication (Table 1). Iron loading decreased mean particle size (P<0.05). Chitosan imparted 
a positive charge to the blank and iron loaded liposomes, confirming its presence on the outer surface 
of the liposomes (Table 1); whereas liposomes without OPC had a net negative zeta potential. Iron 
loading did affect the surface charge (P>0.05) of OPC containing liposomes, but decreased the 
negative surface charge of non-OPC liposomes (P<0.05), through an ionic interaction with the electric 
double layer.  
Caco-2 cells were exposed to increasing concentrations of the liposome formulations standardized at 
specific iron concentrations (20 µM, 50 µM and 100 µM elemental iron), as described previously.28,30 
Cells were also incubated with iron-free liposome formulations to exclude the effect of iron. Cell 
viability in all cases was observed to be at least 85% of control cells at both experimental time points 
(48 h and 72 h: Figure 5). 
To assess the efficacy of the liposome preparations to deliver iron intracellularly, comparative 
absorption experiments were conducted (Figure 6) using the well characterized human intestinal cell 
line Caco-2.37,39 Iron absorption from the liposome preparations was compared to that from free 
FeSO4 solution, as it is generally considered to have the best bioavailability profile amongst iron 
compounds and was employed in the preparation of the liposomal formulation. The overall highest 
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iron absorption was from OPC-Lipo-Fe liposomes (313.46 ± 26.53 ng/mg protein) and was 1.5 fold (P 
< 0.05) higher than for the free FeSO4 control (200.42 ± 24.42 ng/mg protein).  
The cellular uptake characteristics of the liposome formulations were further evaluated qualitatively 
using confocal microscopy. Figure 7 shows confocal micrographs of Caco-2 cells incubated with 
conventional (Lipo-Cou) and OPC liposomes (OPC-Lipo-Cou) loaded with equivalent concentrations 
of the fluorescent dye coumarin-6. The results suggest that the inclusion of the O-palmitoyl chitosan 
influenced the surface charge of the liposomes. It is likely that the OPC was incorporated into the 
liposome structure due to the hydrophobic nature of the chitosan. 
 
Discussion 
Several previous studies have demonstrated the use of hydrophobic chitosan derivatives for 
formulating drug and gene delivery carriers.40-44 In this study a novel hydrophobically-modified 
chitosan derivative was produced by conjugating palmitoyl to the chitosan backbone. The successful 
synthesis and formation of the reaction product OPC was determined by FT-IR and H-NMR and the 
synthesized polymer was further characterized by DSC and XRD. 
Liposomal-iron delivery has been explored previously; however, poor iron loading remains an issue. 
The permeability of the phospholipid bilayer of the lipid vesicles can lead to iron leakage and loss 
during formulation as well as upon storage. Various approaches have previously been explored to 
improve vesicle membrane stability. Inclusion of cholesterol in the formulation increases membrane 
stability, resulting in increased encapsulation efficiencies.45-47 It is thought that the hydroxyl groups in 
the polar head combine with the choline groups of the lipid to create more robust bilayers.48 
Cholesterol is also known to enhance contact between adjacent lipid molecules by having a ‘drying’ 
effect at the lipid-water interface, thereby decreasing bilayer permeability and promoting liposomal 
membrane stability.49 PEGylated polyelectrolytes incorporation into liposomes similarly enhances 
drug delivery. 50 Chitosan incorporation in liposomes is known to have a positive influence on the 
encapsulation characteristics and delivery of liposomes.51-53 Chitosan adsorbs at the vesicle surface 
due to electrostatic interactions with the lipid component thereby creating rigid walled vesicles.54 
Furthermore, chitosan reportedly forms a stable complex with iron that might also result in higher 
incorporation and retention in the vesicle.55 The iron to lipid ratio is another important parameter that 
influences liposomal EE.28 This study employed an iron to lipid ratio of 1:100, as increasing iron 
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concentration has an inverse relationship with liposomal EE, an effect attributed to the strong 
electrolyte behavior of ferrous sulphate.6 O-Palmitoyl chitosan interacts with liposmes due to positive 
charge and hydrophobicity, which we propose is due to the conjugation of palmitoyl groups at the O 
position on the chitosan structure 
We aimed to obtain liposomes in this size range obtained (approx. 200-300 nm); it has been observed 
previously that large sized liposomes are more likely to be unstable and have a tendency for 
flocculation.56 Furthermore, particles in the sub-500 nm range have been reported to be desirable for 
intestinal absorption as they facilitate increased cellular contact and permeation.57 
The high net positive charge of the liposomes suggests electrostatic repulsion between the liposomes 
and is therefore considered favorable for formulation stability.58 Positive charge on the liposome 
surface is also beneficial for interaction and binding with cell surfaces, potentially leading to increased 
cellular entry and uptake. 
The absorption results obtained in our experiments are in agreement with previous in vitro and in vivo 
liposome studies. Hermida and colleagues demonstrated high iron uptake in Caco-2 cells from 
chitosan-coated compared to uncoated liposomes.7 The behavior of chitosan liposomes within the 
intestinal tract was studied by Takeuchi and colleagues using the Wistar rat model.59 Rat intestines 
were examined following administration of liposome preparations, with our without chitosan inclusion; 
highest levels of retention and mucosal penetration was observed with. Chitosan has well 
characterized mucoadhesive properties due to its cationic structure, and also acts as a potent 
permeation enhancer, particularly in the pH environment encountered in the small intestine.60  
Lipid-based carriers are known to possess high cellular permeability, presumably by virtue of ease of 
transport across the phospholipid bilayer of cell membranes.61 Furthermore, the size range of our 
liposome particles is favorable towards intestinal absorption. The influence of particle size on 
intestinal absorption has been explored previously; it is generally thought that particles of 100 – 500 
nm dimensions are most likely to diffuse through the submucosal layer and subsequently enter the 
cell via absorptive endocytosis.62  
The intensity of intracellular green fluorescence emitted by coumarin-6 was considered a marker of 
uptake of the dye-loaded liposomes in Caco-2 cells, as described previously.31,63 Similar studies by 
others have demonstrated that free coumarin-6 does not internalize in Caco-2 cells, and therefore the 
intracellular fluorescent intensity is a direct indicator of the internalization of the dye-loaded 
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liposomes.64,65 As observed in Figure 7, a green fluorescent signal was seen in both images b & e, 
indicating successful entry into the cell of coumarin loaded liposomes, however a noticeably stronger 
signal was observed in Caco-2 cells incubated with OPC-Lipo-Cou (Figure 7 e) compared to Lipo-Cou 
(Figure 7 b. Confocal imaging was performed under similar parameters (sensitivity, gain and offset) to 
allow an unbiased comparison. These results are in agreement with the quantitative uptake data as 
measured by ELISA (Figure 6), and provide further supporting evidence that OPC has a beneficial 
effect on the cellular uptake and internalization characteristics of the liposomes. 
While mechanistic studies of the internalization and intracellular behavior of the liposomes were not 
conducted as part of our experiments, others have suggested potential pathways of cellular uptake 
and transport. Oral micro and nanoparticle drug carriers may gain cellular and subsequent systemic, 
entry via either transcellular or paracellular pathways. Paracellular transport is thought to be limited, 
as the tight junctions between the intestinal enterocytes have an average pore radius of 5 nm.66 Even 
under conditions of induced dilation with pharmacological agents or due to pathological insults these 
junctions may allow the passage of very small sized molecules.67 It is speculated that lipid particles 
are internalized via transcytosis and endocytosis followed by physiological degradation and 
intracellular drug release and subsequent transport across the basolateral membrane. This model is 
consistent with our observations, with higher intracellular levels of coumarin-6 and ferritin protein 
formation observed following loaded liposome administration compared to drug alone. These results 
suggest that the drug released from the liposome formulations is actively processed within the 
enterocyte following cellular liposome uptake.  
 
Conclusions 
The purpose of this work was to synthesize a hydrophobically-modified chitosan derivative and utilize 
this to formulate liposomes for oral drug delivery, using iron sulphate as a model hydrophilic drug. O-
palmitoyl chitosan not only led to increased liposomal iron encapsulation efficiency, but also 
significantly increased iron absorption in Caco-2 cells. These results confirm that this chitosan 
derivative retains the characteristic permeation enhancing properties of chitosan and furthermore its 
inclusion in the liposome may have altered the vesicle microstructure, and influenced greater 
interaction with cell membranes leading to increased cellular uptake.  
14 
In summary, our results present OPC polymer incorporation into liposomes to be utilized for micro and 
nano delivery systems, and demonstrate the potential of OPC liposomes as promising carriers for 
intestinal drug delivery.  
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Tables 
Table 1. Particle size distribution, surface charge and entrapment efficiencies for liposome 
preparations  
Formulation Mean particle size Zeta potential Entrapment efficiency
(nm) * (mV) * (%) *
Lipo-blank 253 ± 17 -28.6 ±8.77
Lipo-Fe 204 ± 22 -9.82 ± 4.33
OPC-Lipo 304 ± 15 33.1 ± 6.39 72.8 ± 1.93
OPC-Lipo-Fe 209 ± 12  27.8 ± 8.67 82.7 ± 2.7
* Values are means ± standard deviation, n = 3
Ab
breviations: nm, nanometers; mV, millivolts; Lipo, liposome; OPC, octyl-palmitoyl chitosan, Fe, iron  
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Figure Legends 
 
Figure 1 FT-IR spectra of chitosan 5k (red) and o-palmitoyl chitosan (black). 
 
Figure 2 H-NMR spectra of a) chitosan 5k (panel a) and b) o-palmitoyl chitosan. 
 
Figure 3 DSC thermogram of a) chitosan (50 °C/min) and b) o-palmitoyl chitosan (20 °C/min). 
 
Figure 4 X-ray powder diffractograms of a) chitosan and b) o-palmitoyl chitosan. 
 
Figure 5 Caco-2 cell viability assessed by MTT assay following a) 48 h and b) 72 h incubation with 
liposome formulations containing increasing drug concentrations (mean ± S.D., n = 6). 
 
Figure 6 Iron absorption by Caco-2 cells incubated with liposome formulations: Intracellular ferritin 
was measured as a marker of iron absorption by ELISA following 22 h incubation after iron uptake 
experiments. Results are shown as mean ± S.D. (n = 6), * and † indicates significant difference (P < 
0.05). 
 
Figure 7 Confocal microscopy images of Caco-2 cells following incubation with coumarin-6 loaded (a-
c) conventional (Lipo-Cou) liposomes and (d-f) OPC liposomes (OPC-Lipo-Cou). Images (a) & (d) 
demonstrate cell nuclei stained with TO-PRO-3 (blue), images (b) & (d) show cell cytoplasm with 
accumulated liposomal coumarin-6, and images (c) & (f) show merged images. Scale shown is 50 
μM. 
